Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication - Wikidata - awgldk - TriplyDB

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

http://www.wikidata.org/entity/Q34627169

about

Cognitive dysfunction and work productivity in major depressive disorder.Sleep complaints in adolescent depression: one year naturalistic follow-up study The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression.Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus.Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis Major depressive disorder: mechanism-based prescribing for personalized medicine Insomnia associated with depressive disorder: primary, secondary, or mixed?IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder.Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission.Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials The complex role of sleep in adolescent depression.Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-α treatment.Improvements in Depression and Changes in Fatigue: Results from the SLAM DUNC Depression Treatment Trial.Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.Concise set of files for smooth return to work in employees with mental disorders.The impact of residual symptoms on relapse and quality of life among Thai depressive patients.Major depressive disorder and sleep disturbance in patients with chronic pain.Clinical relevance of fatigue as a residual symptom in major depressive disorder.Restoration of positive mood states in major depression as a potential drug development target.Antidepressant drug development: Focus on triple monoamine reuptake inhibition.Apathy in Neurodegenerative Diseases: Recommendations on the Design of Clinical Trials.Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression.Insomnia as a Precipitating Factor in New Onset Mental Illness: a Systematic Review of Recent Findings.Changes in depression subtypes for women during treatment with citalopram: a latent transition analysis.Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates.Effects of Antidepressants on Sleep.Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression.Hippocampal-Dependent Antidepressant Action of the H3 Receptor Antagonist Clobenpropit in a Rat Model of Depression.Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice.Italian neurologists' perception on cognitive symptoms in major depressive disorder.Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis.Patient-centered assessment of cognitive symptoms of depression.An open-label study of adjunctive repetitive transcranial magnetic stimulation (rTMS) for partial remission in major depressive disorder.Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder.Characteristics of Residual Symptoms in Korean Patients with Major Depressive Disorder: A Validation Study for the Korean Version of Depression Residual Symptom Scale.Depression and coronary heart disease.Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.A Chinese chan-based mind-body intervention improves sleep on patients with depression: a randomized controlled trial.

P2860

Q30249792-4B5B0211-66C4-4A0F-A20C-C81758A3658C Q34334019-630C64AF-D432-4B87-BCA9-3ED589F7818E Q34335586-4F2A8935-BA64-4274-9A3C-991684C9F783 Q34505291-AA2EEE7E-78B2-4B1E-B4EE-8F3770FF8A40 Q34582365-D4E29348-6F0C-42C3-92FA-A3DA501574D9 Q35284412-3DDE55CB-6C7E-4EFE-81E5-21DCCDB6845F Q35732296-F96FF9FB-8346-4E2D-BA23-432908A79D9E Q36043319-0469AE75-E1C9-4A8C-B642-5FDEC763C9F0 Q36207106-8CF7A1AA-AD34-4140-A364-7FC4A6F2BC39 Q36380157-E89C042C-2ED5-4F06-A303-8C1F4025CD06 Q36709553-0D832EC0-7C51-482F-B539-6F325B54F831 Q36775228-9C635A22-F986-4ED7-8AD7-81982246F88F Q36998562-A44011A3-8C87-4117-AA7B-0EB5B96D6799 Q37309556-05D3A7CB-9DE9-4E24-A656-15D0B218C83E Q37364949-0E2BB6C7-DD03-4B6A-AF11-A7316FCB54F2 Q37510121-2E23A143-BCB1-4A9A-9C39-08022B183A81 Q37609818-33DFDAE0-F602-4D35-905A-2410E7CC6AAD Q38151637-17BEF882-4CD5-4E20-ABB5-BC02062F8138 Q38210460-88067F95-1825-4E5A-8088-695E6F3B69BE Q38260259-A2CC7036-1C24-4963-98AE-7CF45D93D480 Q38391306-8E941C1A-9EEF-4B89-A768-15482691A415 Q39328768-E8F4964A-7E22-468A-AFF0-7AE8E22D70AD Q39375201-A644CED5-E3F9-425D-8126-DE5C98A14FB9 Q40071013-9F3217FD-CA8E-4C57-A2E5-ED6A9B41A992 Q40264491-C301FBD2-FBB9-4CA7-84B9-2E09319344A5 Q41310657-208B085A-4D07-449D-8AB9-A0A1FEAB569E Q41994846-A1328157-2237-4CC8-BF86-C4A18C1B7709 Q42002128-D34F94FF-B406-4B24-8606-5E36E8922D19 Q45937835-07E95E36-5EC4-4D39-8349-AF89021BAE1F Q46674667-3BD7C941-4736-4067-86ED-D1627BCF4C38 Q47550351-65B4B714-468F-4F1F-A7A3-D4642EC7B4C5 Q48056101-7611F5D8-6A8D-481C-9ECC-E31FA0DE5A54 Q48057578-F6CCD70A-FD74-4252-B297-CC92C318EFEE Q48421933-AE639A1F-9452-4967-8FBA-C31E68B631AE Q48729844-67C140B8-2CCE-4449-91F2-F7A1AD4EC953 Q48773640-6D99B38B-7397-4680-801A-6686882EF1AB Q53081881-082B05A2-471D-4E14-A025-14B72FE3CF29 Q53131906-50BF97EA-D487-4CFD-95AF-45F050B8506C Q55132660-24B19100-3FC0-474D-BE7A-994F74F8A293 Q55405881-A7EF22F8-914A-4113-AC86-D4B54D4C6223

P2860

Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication

http://www.wikidata.org/entity/Q34627169

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Residual symptoms in depressed ...... t to antidepressant medication

@ast

Residual symptoms in depressed ...... t to antidepressant medication

@en

Residual symptoms in depressed ...... t to antidepressant medication

@nl

type

label

Residual symptoms in depressed ...... t to antidepressant medication

@ast

Residual symptoms in depressed ...... t to antidepressant medication

@en

Residual symptoms in depressed ...... t to antidepressant medication

@nl

prefLabel

Residual symptoms in depressed ...... t to antidepressant medication

@ast

Residual symptoms in depressed ...... t to antidepressant medication

@en

Residual symptoms in depressed ...... t to antidepressant medication

@nl

P1433

Q34627169-1106B62B-B216-40C6-82D4-785A70247C10

P1476

Q34627169-07720D63-C1D2-43AF-9480-46436D8D5B78

P2093

Q34627169-01601301-8898-4056-9C7C-AA48B8906F35

Q34627169-0C549D87-1ECD-4818-98E6-79DB03B21AF9

Q34627169-0F439F6F-AA8B-42FD-9BB2-F7B59ACF5618

Q34627169-1D90E12A-A761-4F66-A3FA-786E75A5360A

Q34627169-22168E5A-27D1-4009-988F-696BB165C79E

Q34627169-22BB38E1-8393-440F-A833-21C6DDF6FE11

Q34627169-9CBAF15A-6F78-4970-8080-F4A7A0FAD4E2

Q34627169-E55BC17D-B233-480B-A286-BA3D246E2E97

P2860

Q34627169-019F9109-5FEF-45CC-8641-E0EB17B6F55D

Q34627169-0475C0B3-3B46-4087-9BA0-907FFD10E551

Q34627169-155820B6-FF62-4572-BF4C-81EF3D9DF8FD

Q34627169-1AD97ACC-D023-4509-9140-CD813F518981

Q34627169-1DB7BB35-FE3C-4B55-BE51-7F9466D3CB4D

Q34627169-207898BD-6026-47E6-BBDA-6D6B2079ACC2

Q34627169-21541C61-91A8-4898-86F8-D6249DF4FE52

Q34627169-225BD954-E866-4385-988C-34455F1B1A26

Q34627169-37874C55-55D0-45D8-ABC0-F64D70F3D339

Q34627169-43BD6DEA-7DC4-4EF4-8113-C92721F7D289

P304

Q34627169-80580FE0-F748-42B5-ADC1-E1679EDFE9B1

P31

Q34627169-286A9DC5-9E45-4E26-8ECB-01A8B2AB806E

P356

Q34627169-1657E041-80BB-4290-BB66-FCFB597085A9

P407

Q34627169-020A16A3-DC4C-4842-8BF6-86EA72F3D1ED

P433

Q34627169-03E15C50-8716-4C0A-A50C-6F91ECD89399

P478

Q34627169-6F3307E5-12FD-4DC5-A199-E3E47D39CCD0

P50

Q34627169-0D0B85FB-170F-4A43-B971-F9827E5B387F

Q34627169-D5808A18-D68B-432C-B6F2-5472206B90BD

P577

Q34627169-5D086A6B-FF59-404D-9A83-BD54607E83D4

P698

Q34627169-9752DA54-954C-45F1-8689-1008C8D6225B

P932

Q34627169-204FCFCD-C8F1-468D-8C6D-5AF66AA39EF1

P356

JCP.0B013E31820EBD2C

P1433

Journal of Clinical Psychopharmacology

P1476

Residual symptoms in depressed ...... t to antidepressant medication

@en

P2093

Andrew A Nierenberg

http://www.w3.org/2001/XMLSchema#string

David Morris

http://www.w3.org/2001/XMLSchema#string

Diane Warden

http://www.w3.org/2001/XMLSchema#string

Ian Cook

http://www.w3.org/2001/XMLSchema#string

Jonathan W Stewart

http://www.w3.org/2001/XMLSchema#string

Madhukar H Trivedi

http://www.w3.org/2001/XMLSchema#string

Mustafa M Husain

http://www.w3.org/2001/XMLSchema#string

Shawn M McClintock

http://www.w3.org/2001/XMLSchema#string

P2860

A rating scale for depression

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study

Which depressive symptoms remain after response to cognitive therapy of depression and predict relapse and recurrence?

The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity.

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort.

Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression

Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression.

P304

180-186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JCP.0B013E31820EBD2C

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Augustus John Rush

Stephen R. Wisniewski

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21346613

http://www.w3.org/2001/XMLSchema#string

P932

3677201

http://www.w3.org/2001/XMLSchema#string